AstraZeneca Pharma India plans to launch cancer drug; stock opens positive
AstraZeneca Pharma India plans to launch cancer drug; stock opens positive

AstraZeneca Pharma India plans to launch cancer drug; stock opens positive

DSIJ Intelligence Article rating: 5.0

Acalabrutinib 100 mg capsules (Calquence) are used to treat patients suffering from mantle cell lymphoma (MCL) especially those, who have received at least one prior therapy. It is also used for the treatment of chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 4.2

The market opened in green October 16, 2020, overall volumes in futures & options currently stand at 8,37,12,303 contracts with a turnover of Rs. 58,24,762.54 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 3.8

The market opened in green October 16, 2020, overall volumes in futures & options currently stand at 8,37,12,303 contracts with a turnover of Rs. 58,24,762.54 crore.

Nifty trend for Friday and stocks in news: Tech Mahindra, Bharti Airtel, AstraZeneca and Persistent Systems
Nifty trend for Friday and stocks in news: Tech Mahindra, Bharti Airtel, AstraZeneca and Persistent Systems

Nifty trend for Friday and stocks in news: Tech Mahindra, Bharti Airtel, AstraZeneca and Persistent Systems

DSIJ Intelligence-3 Article rating: 4.8

Thursday’s market crash proved the age-old saying of D-Street, ‘bulls walk up the stairs, bears jump out of the window’. Nevertheless, on Thursday, Nifty witnessed a scary fall and recorded its biggest single-day fall in percentage terms after May 18.

RSS
First28002801280228032805280728082809Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR